この専門家をプロジェクトに採用したいですか? 見積もりを依頼 無料で。
プロフィール詳細
Dr. Damien T.に依頼
France
Freelance scientific expert specialized in preclinical development - technical writer
プロフィール概要
専門分野
サービス
Writing
Clinical Trial Documentation,
Medical Writing,
Non-Medical Regulatory Writing,
Technical Writing,
Business & Legal Writing,
Copywriting,
Newswriting,
Audio Transcription,
General Proofreading & Editing,
Translation
職務経験
Chief Scientific Officer
ENCEFA
9月 2015 - 現在 ![]()
Founder/CSO
ENCEFA
10月 2015 - 10月 2023
Chief Project Manager
Pharnext
3月 2014 - 9月 2015
Project manager
Pharnext
3月 2014 - 9月 2015 ![]()
Sientific consultant
Subventium
1月 2011 - 7月 2013
学歴
Université Pierre et Marie Curie
9月 2007 - 12月 2010 ![]()
PhD
Université Pierre et Marie Curie (Paris VI) - France
1月 2007 - 12月 2010
M.Sc Biochemistry and Genetics
AGROCAMPUS OUEST
9月 2004 - 6月 2007 ![]()
認定資格
- 認定資格の詳細は未入力です。
出版物
JOURNAL ARTICLE
Damien Toulorge, Serge Guerreiro, Anne-Laure Privat, Laurence Bressac(2020). CD38 in Neurodegeneration and Neuroinflammation . Cells. 9. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 471. {MDPI} {AG}
Damien Toulorge and Anthony H. V. Schapira and Rodolphe Hajj(2016). Molecular changes in the postmortem parkinsonian brain . Journal of Neurochemistry. 139. Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 27--58. Wiley
Rodolphe Hajj and Aude Milet and Damien Toulorge and Nathalie Cholet and Julien Laffaire and Julie Foucquier and Sandra Robelet and Richard Mitry and Mickael Guedj and Serguei Nabirotchkin and Ilya Chumakov and Daniel Cohen(2015). Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease . Scientific Reports. 5. (1). Springer Science and Business Media {LLC}
Ilya Chumakov and Serguei Nabirotchkin and Nathalie Cholet and Aude Milet and Aur{\'{e}}lie Boucard and Damien Toulorge and Yannick Pereira and Esther Graudens and Sory Traor{\'{e}} and Julie Foucquier and Mickael Guedj and Emmanuel Vial and Noëlle Callizot and R{\'{e}}my Steinschneider and Tangui Maurice and Viviane Bertrand and Catherine Scart-Gr{\`{e}}s and Rodolphe Hajj and Daniel Cohen(2015). Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy . Scientific Reports. 5. (1). Springer Science and Business Media {LLC}
Patrick P. Michel and Damien Toulorge and Serge Guerreiro and Etienne C. Hirsch(2013). Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease . The FASEB Journal. 27. (9). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 3414--3423. Wiley
Damien Toulorge and Serge Guerreiro and Audrey Hild and Uwe Maskos and Etienne C. Hirsch and Patrick P. Michel(2011). Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca
2+ . The FASEB Journal. 25. (8). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 2563--2573. Wiley
Damien Toulorge and Serge Guerreiro and Etienne C. Hirsch and Patrick P. Michel(2010). KATP channel blockade protects midbrain dopamine neurons by repressing a glia-to-neuron signaling cascade that ultimately disrupts mitochondrial calcium homeostasis . Journal of Neurochemistry. 114. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 553--564. Wiley
Serge Guerreiro and Aur{\'{e}}lie Ponceau and Damien Toulorge and Elodie Martin and Daniel Alvarez-Fischer and Etienne C. Hirsch and Patrick P. Michel(2009). Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization . Journal of Neurochemistry. 109. (4). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1118--1128. Wiley
Serge Guerreiro and Damien Toulorge and Etienne Hirsch and Marc Marien and Pierre Sokoloff and Patrick P. Michel(2008). Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels . Molecular Pharmacology. 74. (4). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 980--989. American Society for Pharmacology {\&} Experimental Therapeutics ({ASPET})